How Real-World Regorafenib Dosing Correlates With Prior Sorafenib Treatment in HCC
Richard Finn, MD, discusses the interim results of the REFINE Study, which tests the real-world dosing of regorafenib in patients with unrespectable hepatocellular carcinoma.
Richard Finn, MD, a hematologic oncologist at the UCLA Jonsson Comprehensive Cancer Center, discusses the interim results of the REFINE Study, which tests the real-world dosing of regorafenib (Stivarga) in patients with unrespectable hepatocellular carcinoma (HCC).
According to Finn, all of the patients in the study were previously treated with sorafenib (Nexavar). Care providers either administered a full dose of regorafenib, or the dose of their choice. Some patients were administered 120 mg or as little as 80 mg of regorafenib daily. Dosing seemed to be based on the prior sorafenib dose, Finn notes.
Survival in the group was about 13 months. Adverse events were similar to those observed in the RESORCE study (NCT01774344). Additionally, according to Finn, the safety profiles was similar regardless of the dose. Dose de-escalation was also determined to be related to prior sorafenib.
Hope Beyond Surgery: Optimizing Care for Cholangiocarcinoma
February 15th 2024In an interview for Cholangiocarcinoma Awareness Day, Domenech Asbun, MD, discussed how the management of cholangiocarcinoma continues to evolve and addressed unmet needs in early detection and systemic therapy.
Read More
Durvalumab/Bevacizumab/TACE Significantly Extends Survival in HCC
February 6th 2024In an interview with Targeted Oncology, Bruno Sangro, MD, PhD, discussed the potential durvalumab, bevacizumab, and TACE has to set a new standard-of-care among patients with unresectable hepatocellular carcinoma.
Read More
Regorafenib Discontinuation More Likely With Poor Liver Function in Liver Cancer
January 19th 2024Patients with unresectable hepatocellular carcinoma and poor liver function were more likely to experience serious adverse effects leading to regorafenib treatment discontinuation, researchers have found.
Read More
